Related Experiment Video
Updated: Jun 28, 2026
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
In vivo inhibition of angiogenesis by htsFLT01/MiRGD nano complex
Mohadeseh Khoshandam1, Zahra-Soheila Soheili1, Saman Hosseinkhani2
1Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Abstract:
The inhibition of angiogenesis is a crucial therapeutic strategy in cancer treatment, as it limits tumor growth and metastasis. In this study, we investigate the anti-angiogenic potential of a novel htsFLT01/MiRGD nanocomplex, designed to target key angiogenesis markers in cancer. This nanocomplex integrates the anti-angiogenic fusion protein htsFLT01 with the MiRGD peptide to enhance its efficacy. Our findings demonstrate that htsFLT01/MiRGD effectively suppresses angiogenesis both in vitro and in vivo, particularly in breast cancer models. Histological and molecular analyses reveal a significant reduction in blood vessel formation, accompanied by structural changes in tumor tissue. Furthermore, the expression levels of key angiogenesis-related genes, including VEGF, VEGFR, and CD31, are markedly downregulated, highlighting the therapeutic potential of this nanocomplex. Beyond its anti-angiogenic effects, the treatment also induces apoptosis and inhibits tumor cell proliferation, reinforcing its role as a promising targeted therapy for angiogenesis-dependent malignancies. These results underscore the potential of htsFLT01/MiRGD in cancer treatment and pave the way for future clinical applications in anti-angiogenic therapies.
Insights
A novel nanocomplex effectively inhibits angiogenesis, reducing tumor growth and metastasis in breast cancer models. This targeted therapy shows promise for treating angiogenesis-dependent cancers.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Angiogenesis inhibition is a key cancer treatment strategy, targeting tumor growth and metastasis.
- Novel therapeutic agents are needed to effectively target angiogenesis pathways.
- Tumor angiogenesis relies on specific molecular markers and signaling pathways.
Purpose of the Study:
- To evaluate the anti-angiogenic potential of the htsFLT01/MiRGD nanocomplex.
- To investigate the efficacy of this novel agent in preclinical cancer models, particularly breast cancer.
- To elucidate the molecular mechanisms underlying the nanocomplex's anti-angiogenic effects.
Main Methods:
- In vitro and in vivo studies were conducted to assess anti-angiogenic activity.
- Histological and molecular analyses were performed on tumor tissues.
- Gene expression levels of angiogenesis markers (VEGF, VEGFR, CD31) were quantified.
Main Results:
- The htsFLT01/MiRGD nanocomplex significantly suppressed angiogenesis in vitro and in vivo.
- Tumor histological analysis showed reduced blood vessel formation and altered tissue structure.
- Key angiogenesis-related gene expression (VEGF, VEGFR, CD31) was markedly downregulated.
- The treatment also induced apoptosis and inhibited tumor cell proliferation.
Conclusions:
- The htsFLT01/MiRGD nanocomplex demonstrates potent anti-angiogenic activity.
- This agent shows significant therapeutic potential for angiogenesis-dependent cancers, including breast cancer.
- The findings support further clinical investigation of htsFLT01/MiRGD for targeted anti-angiogenic therapy.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply